BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 22421527)

  • 1. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
    Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
    Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
    Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
    Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
    Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
    Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient abnormal myelopoiesis in neonates: GATA get the diagnosis.
    Bombery M; Vergilio JA
    Arch Pathol Lab Med; 2014 Oct; 138(10):1302-6. PubMed ID: 25268193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
    Anoop P; Atra A
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
    Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
    Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of myeloid leukemia in children with Down syndrome.
    Saida S
    Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haematopoietic development and leukaemia in Down syndrome.
    Roberts I; Izraeli S
    Br J Haematol; 2014 Dec; 167(5):587-99. PubMed ID: 25155832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematological disorders in children with Down syndrome.
    Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21.
    Yuzawa K; Terui K; Toki T; Kanezaki R; Kobayashi A; Sato T; Kamio T; Kudo K; Sasaki S; Endo M; Ozono S; Nomura K; Ito E
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28188. PubMed ID: 32020774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome.
    Mizuta S; Yamane N; Mononobe S; Watanabe A; Kitamura R; Takahara T; Matsushima C; Yoshida A; Okamoto S; Tanaka K; Iwai A; Ikegawa A; Wada T; Usami I; Maihara T; Komai T; Heike T; Nishida Y; Kobayashi K
    Int J Lab Hematol; 2022 Apr; 44(2):349-355. PubMed ID: 34761527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myeloid proliferations related to Down syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
    Garnett C; Cruz Hernandez D; Vyas P
    IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
    Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient abnormal myelopoiesis in non-Down syndrome neonate.
    Ohkawa T; Miyamoto S; Sugie M; Tomizawa D; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
    Pediatr Int; 2015; 57(1):e14-7. PubMed ID: 25711269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.